Publikationen der Klinik für Strahlentherapie und Onkologie

Hier finden Sie die Publikationen der Klinik für Strahlentherapie und Onkologie der letzten Jahre.

Publikationen 2020

Diefenhardt M, Ludmir EB, Hofheinz RD, Ghadimi M, Minsky BD, Rödel C, Fokas E. Association of sex with toxic effects, treatment adherence, and oncologic outcomes in the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 Phase 3 randomized clinical trials of rectal cancer. JAMA Oncol 2019; epub ahead of print. (Pubmed-Link).

Fietkau R, Hecht M, Hofner B, Lubgan D, Iro H, Gefeller O, Rödel C, Hautmann MG, Kölbl O, Salay A, Rübe C, Melchior P, Breinl P, Krings W, Gripp S, Wollenberg B, Keerl R, Schreck U, Siekmeyer B, Grabenbauer GG, Balermpas P, PacCis-Study Group.. Randomized phase-III-trial of concurrent chemoradiation for locally advanced head and neck cancer comparing dose reduced radiotherapy with paclitaxel/cisplatin to standard radiotherapy with fluorouracil/cisplatin: The PacCis-trial, Radiother Oncol 2020;144:209-217. (Pubmed-Link).

Fokas E, Glynne-Jones R, Appelt A, Beets-Tan R, Beets G, Haustermans K, Marijnen C, Minsky BD, Ludmir E, Quirke P, Sebag-Montefiore D, Garcia-Aguilar J, Gambacorta MA, Valentini V, Buyse M, Rödel C. Outcome measures in multimodal rectal cancer trials. Lancet Oncol 2020 ;21:e252-e264. (Pubmed Link).

Freund I, Hehlgans S, Martin D, Ensminger M, Fokas E, Claus Rödel C, Löbrich M, Rödel F. Fractionation-dependent radiosensitization by molecular targeting of Nek1. Cells 2020;9:E1235. (Pubmed-Link).

Gaipl U, Multhoff G, Pockley G, Rödel F.  Editorial: Radioimmunotherapy—Translational Opportunities and Challenges. Front Oncol 2020;10:190. (Pubmed-Link).

Ludmir EB, Fuller CD, Moningi S, Mainwaring W, Lin TA, Miller AB, Jethanandani A, Espinoza AF, Verma V, Smith BD, Smith GL, VanderWalde NA, Holliday EB, Guadagnolo BA, Stinchcombe TE, Jagsi R, Gomez DR, Minsky BD, Rödel C, Fokas E. Sex-Based Disparities Among Cancer Clinical Trial Participants. J Natl Cancer Inst 2020;112:211-213. (Pubmed-Link).

Martin D, Rödel F, von der Grün J, Rödel C, Fokas E. Acute organ toxicity correlates with better clinical outcome after chemoradiotherapy in patients with anal carcinoma. Radiother Oncol 2020;epub ahead of print (Pubmed-Link).

Martin D, Balermpas P, Gollrad J, Weiß C, Valentini C, Stuschke M, Schäfer H, Henckenberens C, Debus J, Krug D, Kuhnt T, Brunner T, Bostel T, Engenhart-Cabillic R, Nestle U, Combs S, Belka C, Hautmann M, Hildebrandt G, Gani C, Polat B, Rödel C, Fokas E. RADIANCE - Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial. Clin Transl Radiat Oncol 2020;23:43-49. (Pubmed-Link).

Michaelis M, Voges Y, Rothweiler F, Weipert F, von Deimling A, Westermann F, Rödel F, Wassa M, Cinatl J. Testing of the survivin suppressant YM155 in a large panel of drug-resistant neuroblastoma cell lines. Cancers 2020;12:E577. (Pubmed-Link).

Michaelis M, Wass M, Reddin I, VogesY, RothweilerF, Hehlgans S, MernbergerM, NistA, Stiewe T, Rödel F, Cinatl J. Drug-adapted cancer cell lines reveal drug-induced heterogeneity and enable the identification of specific biomarkers for the acquired resistance setting, Cancers 2020;12:E1080. (Pubmed-Link).

Marijnen CAM, Peters FP, Rödel C, Bujko K, Haustermans K, Fokas E, Glynne-Jones R, Valentini V, Spindler KG, Guren MG, Maignon P, Calvo FA, Pares O, Glimelius B, Sebag-Montefiore D. International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic. Radiother Oncol 2020 epub ahead of print (Pubmed-Link)

Rödel F, Arenas M, Ott O, Fournier C, Georgakilas AG, Tapio S, Trott KR, Gaipl US. Low-dose radiation therapy for COVID-19 pneumopathy: What are the evidences? Strahlenther Onkol 2020;epub ehaed of print (Pubmed-Link).

Schmid SC, Koll FJ, Rödel C, Maisch P, Sauter A, Beckert F, Seitz A, Kübler H, Flentje M, Chun F, Combs SE, Schiller K, Gschwend JE, Retz M. Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer - study protocol of a prospective, single arm, multicenter phase II trial (RACE IT). BMC Cancer 2020;20:8. (Pubmed-Link).

Schmidt S, Linge A, Großer M, Lohaus F, Gudziol V, Nowak A, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rödel C, Schäfer H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch S, Combs SE, Mönnich D, Zips D, Baretton GB, Buchholz F, Baumann M, Krause M, Löck S; DKTK-ROG. Comparison of GeneChip, nCounter and real-time polymerase chain reaction based gene expressions predicting loco-regional tumour control after primary and postoperative radiochemotherapy in head and neck squamous cell carcinoma. J Mol Diagn 2020, epub ahead of print (Pubmed-Link).

Schmitt D, Blanck O, Gauer T, Fix MK, Brunner TB, Fleckenstein J, Loutfi-Krauss B, Manser P, Werner R, Wilhelm ML, Baus WW, Moustakis C. Technological quality requirements for stereotactic radiotherapy : Expert review group consensus from the DGMP Working Group for Physics and Technology in Stereotactic Radiotherapy.  Strahlenther Onkol 2020, epub ahead of print. (Pubmed-Link)

Schulz M, Michels B, Niesel K, Stein S, Farin H, Rödel F, Sevenich L. Cellular and molecular changes of brain metastases-associated myeloid cells during disease progression and therapeutic response iScience 2020; accepted (Pubmed-Link).

Strouthos I, Tselis N, Ferentinos K, Karagiannis E, Milickovic N, Chatzikonstantinou G, Feder O, Zamboglou N. Intraluminal high-dose-rate brachytherapy - an alternative organ-preserving approach for primary male urothelial carcinoma with panurethral involvement. Pract Radiat Oncol 2020;10:e53-e56